AU2004289083B2 - Use of glucosidase inhibitors for therapy of mucovisidosis - Google Patents

Use of glucosidase inhibitors for therapy of mucovisidosis Download PDF

Info

Publication number
AU2004289083B2
AU2004289083B2 AU2004289083A AU2004289083A AU2004289083B2 AU 2004289083 B2 AU2004289083 B2 AU 2004289083B2 AU 2004289083 A AU2004289083 A AU 2004289083A AU 2004289083 A AU2004289083 A AU 2004289083A AU 2004289083 B2 AU2004289083 B2 AU 2004289083B2
Authority
AU
Australia
Prior art keywords
dnj
cells
cftr
inhibitor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004289083A
Other languages
English (en)
Other versions
AU2004289083A1 (en
Inventor
Frederic Becq
Caroline Norez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2004289083A1 publication Critical patent/AU2004289083A1/en
Application granted granted Critical
Publication of AU2004289083B2 publication Critical patent/AU2004289083B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2004289083A 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis Ceased AU2004289083B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0313134A FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
FR0313134 2003-11-07
PCT/FR2004/002858 WO2005046672A2 (fr) 2003-11-07 2004-11-05 Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose

Publications (2)

Publication Number Publication Date
AU2004289083A1 AU2004289083A1 (en) 2005-05-26
AU2004289083B2 true AU2004289083B2 (en) 2009-12-03

Family

ID=34508347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004289083A Ceased AU2004289083B2 (en) 2003-11-07 2004-11-05 Use of glucosidase inhibitors for therapy of mucovisidosis

Country Status (24)

Country Link
US (2) US7973054B2 (https=)
EP (1) EP1680105B1 (https=)
JP (1) JP4740868B2 (https=)
KR (2) KR100979276B1 (https=)
CN (1) CN100534432C (https=)
AT (1) ATE423561T1 (https=)
AU (1) AU2004289083B2 (https=)
BR (1) BRPI0416228A (https=)
CA (1) CA2545133C (https=)
CY (1) CY1110468T1 (https=)
DE (1) DE602004019674D1 (https=)
DK (1) DK1680105T3 (https=)
ES (1) ES2321725T3 (https=)
FR (1) FR2861991B1 (https=)
HR (1) HRP20090159T1 (https=)
IL (1) IL175453A (https=)
NO (1) NO336904B1 (https=)
NZ (1) NZ547261A (https=)
PL (1) PL1680105T3 (https=)
PT (1) PT1680105E (https=)
RU (1) RU2358725C2 (https=)
SI (1) SI1680105T1 (https=)
WO (1) WO2005046672A2 (https=)
ZA (1) ZA200603726B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406143B2 (en) 2006-05-16 2019-09-10 Amicus Therapeutics, Inc. Methods for treatment of fabry disease

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2007241622A1 (en) * 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
EP2352828B1 (en) * 2008-09-11 2015-02-25 Galapagos N.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
ITFE20080032A1 (it) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
KR20160055916A (ko) * 2013-09-16 2016-05-18 이머전트 바이롤로지 엘엘씨 데옥시노지리마이신 유도체 및 그의 이용 방법
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
EP3448410A1 (en) * 2016-04-29 2019-03-06 Institut Pasteur Methods and compositions for modifying cystic fibrosis transmembrane conductance regulator activity
US10478427B2 (en) * 2016-07-07 2019-11-19 National University Corporation Chiba University Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
AU2018278247B2 (en) * 2017-06-01 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
CN108187051A (zh) * 2018-01-30 2018-06-22 中国药科大学 α-L-岩藻糖苷酶及抑制剂用于制备防治心肌缺血损伤的药物的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002862A1 (en) * 1999-06-29 2001-01-11 National Research Council Of Canada Methods to detect protein trafficking disorders
WO2003037265A2 (en) * 2001-10-30 2003-05-08 Thomas Jefferson University Method of treating viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
TW275621B (https=) * 1992-10-27 1996-05-11 Merck & Co Inc
WO1998020123A2 (en) * 1996-11-04 1998-05-14 Institut Curie Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins
ID21411A (id) * 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
AU7398900A (en) * 1999-09-23 2001-04-24 Hospital For Sick Children, The Three-dimensional structure and crystal of a class i alpha1,2-mannosidase, and methods of use thereof
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
US7071341B2 (en) * 2003-02-28 2006-07-04 Council Of Scientific And Industrial Research α-Glucosidase inhibitors and their synthesis from a natural source

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002862A1 (en) * 1999-06-29 2001-01-11 National Research Council Of Canada Methods to detect protein trafficking disorders
WO2003037265A2 (en) * 2001-10-30 2003-05-08 Thomas Jefferson University Method of treating viral infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406143B2 (en) 2006-05-16 2019-09-10 Amicus Therapeutics, Inc. Methods for treatment of fabry disease

Also Published As

Publication number Publication date
CA2545133A1 (fr) 2005-05-26
FR2861991A1 (fr) 2005-05-13
PL1680105T3 (pl) 2009-07-31
PT1680105E (pt) 2009-05-20
NO336904B1 (no) 2015-11-23
ZA200603726B (en) 2007-12-27
DK1680105T3 (da) 2009-06-29
KR20060130058A (ko) 2006-12-18
FR2861991B1 (fr) 2008-01-18
NO20062617L (no) 2006-07-25
EP1680105A2 (fr) 2006-07-19
KR20100038452A (ko) 2010-04-14
IL175453A (en) 2012-09-24
KR100979276B1 (ko) 2010-08-31
ATE423561T1 (de) 2009-03-15
US8242136B2 (en) 2012-08-14
SI1680105T1 (sl) 2009-08-31
DE602004019674D1 (de) 2009-04-09
ES2321725T3 (es) 2009-06-10
WO2005046672A2 (fr) 2005-05-26
CA2545133C (fr) 2013-04-16
CY1110468T1 (el) 2015-04-29
IL175453A0 (en) 2008-03-20
US20070213357A1 (en) 2007-09-13
CN1897933A (zh) 2007-01-17
RU2006119914A (ru) 2007-12-20
NZ547261A (en) 2009-11-27
EP1680105B1 (fr) 2009-02-25
HRP20090159T1 (en) 2009-05-31
JP4740868B2 (ja) 2011-08-03
JP2007510699A (ja) 2007-04-26
AU2004289083A1 (en) 2005-05-26
US20110269795A1 (en) 2011-11-03
US7973054B2 (en) 2011-07-05
RU2358725C2 (ru) 2009-06-20
WO2005046672A3 (fr) 2005-09-15
BRPI0416228A (pt) 2007-01-02
CN100534432C (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
US8242136B2 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
Kang et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG
US20090048260A1 (en) Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells
US8492420B2 (en) Use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells
NO322137B1 (no) Anvendelse av cholinesterase-inhibitorer for fremstilling av et farmasoytisk preparat.
US20070249622A1 (en) Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases
NZ528042A (en) Nicotinic receptor agonists particularly DMPP for the treatment of inflammatory diseases of the lungs
US7718694B2 (en) Compositions and methods for therapy for diseases characterized by defective chloride transport
Gross et al. Fluticasone Propionate Versus Triamcinolone Acetonide
Takagi et al. Comparative studies on interaction between theophylline and quinolones
US7605153B2 (en) Use of paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells
MXPA06005086A (en) Use of glucosidase inhibitors for therapy of mucovisidosis
US8252958B2 (en) Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells
Tateishi et al. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test
Okoye et al. Physicochemical equivalence of some brands of Nifedipine retard tablets available in Nigeria
TENDINITIS et al. Highlights of prescribing information
Injection Highlights of prescribing information
PLAGUE Division of Anti-Infective Products Office of Antimicrobial Products Center for Drug Evaluation and Research, FDA
TENDINITIS et al. CIPROFLOXACIN INJECTION.
Cui et al. Articles in PresS. Am J Physiol Lung Cell Mol Physiol (July 24, 2015). doi: 10.1152/ajplung. 00181.2015
GRAVIS CIPROFLOXACIN IN DEXTROSE-ciprofloxacin injection, solution Hospira, Inc
Files et al. Label: CIPROFLOXACIN tablet, film coated
JPH045232A (ja) Ｋ↑＋チャンネルアクチベーターの喘息予防用途
IT9047973A1 (it) Impiego di attivatori dei canali potassici per la profilassi dell'asma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired